Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Antipodes Global Value Fund. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
Positioning StanceCONSTRUCTIVE
Market CapAll Cap
GeographyGlobal
Digest Analysis
Quick Take
"Constructive on expanding market breadth, rotating capital into mispriced AI and memory beneficiaries like Samsung and Alibaba and initiating Biogen, while harvesting fully valued cyclical building products and utilities."
Executive Summary
The Antipodes Global Value strategy outperformed its benchmark over the third quarter of 2026 and finished in-line over the trailing twelve months, while underperforming the MSCI ACWI Value Index. Specific fund net return figures were not explicitly published in the commentary. Stock selection within information technology, consumer discretionary, and communication services served as the primary drivers of relative performance, while allocations to financials and healthcare detracted. From a regional perspective, North American exposures contributed positively, bolstered by an underweight stance in Korea, whereas European and Emerging Markets positions detracted. Overall portfolio exposure was rotated by increasing net technology weightings while trimming capital across utilities, materials, consumer staples, and financials.
Macroeconomic conditions during the quarter were characterized by heightened volatility, an accelerating artificial intelligence infrastructure buildout, and a synchronized shift toward monetary tightening. Surging Middle East tensions and disruption in the Strait of Hormuz drove Brent Crude past $100 per barrel, reigniting inflation fears and prompting a global bond sell-off where the US 10-year Treasury yield rose to 5.3%. In response to persistent price pressures, the Federal Reserve delivered a 25 basis point rate hike, accompanied by rate increases from the European Central Bank and the Bank of Japan. Against this backdrop, Antipodes positioned the strategy around four key themes: energy and power infrastructure, AI disruption opportunities, quality compounders at trough multiples, and AI-agnostic industries benefiting from demographic aging.
Portfolio activity reflected disciplined rebalancing and capital redeployment toward mispriced compounders. The fund initiated new long positions in Samsung Electronics on High Bandwidth Memory (HBM4) market share opportunities, Biogen on commercial pipeline inflection, and Skyworks on analog consolidation synergies. The team also augmented its stake in Alibaba, citing accelerating cloud revenue growth and trough multiples. These additions were funded by taking profits and fully exiting RWE, Kokusai Electric, and Owens Corning following strong price appreciation that narrowed their respective margins of safety.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
65%
CautiousHigh
Moderate (65%)
Antipodes exhibits moderate-to-high conviction through decisive portfolio rotations, initiating new long stakes in Samsung, Biogen, and Skyworks while completely exiting RWE, Kokusai Electric, and Owens Corning on valuation grounds. However, individual portfolio weightings are not explicitly reported, and the strategy maintains a diversified footprint spanning multiple global sectors and regions.
Growth Outlook
55%
BearishBullish
Neutral (55%)
The manager maintains a balanced, mildly constructive stance, noting that global equity gains have been narrowly concentrated in mega-cap technology as market breadth deteriorated. While acknowledging macroeconomic friction from synchronized interest rate hikes and Brent crude crossing $100, Antipodes sees compelling opportunities for value-oriented rotation.
Risk Appetite
60%
DefensiveAggressive
Balanced (60%)
Positioning reflects a measured willingness to assume equity risk by net-increasing technology weightings and adding to turnaround situations like Alibaba and Biogen. Concurrently, the manager trimmed defensive utilities, materials, and consumer staples, maintaining an active, non-defensive stance.
Capital Deployment
60%
De-riskingDeploying
Net Neutral (60%)
Portfolio actions indicate net-neutral to mild capital deployment, balancing aggressive new position initiations in Samsung, Biogen, and Skyworks against total exits in RWE, Kokusai Electric, and Owens Corning.
Forward Guidance
75%
CautiousExpansionary
Expansionary (75%)
The fund displays an active forward deployment bias, having deployed capital into multiple new entries such as Samsung and Biogen while topping up depressed shares of Alibaba. Capital was systematically freed up by harvesting winners and exiting positions reaching full valuation targets.
Language Signal
60%
BearishBullish
Balanced (60%)
Commentary balances constructive language around undemanding valuations, accelerating cloud engines, and pipeline turning points against warnings of narrow market breadth, customer concentration, and monetary tightening pressures.
Perceived Risk
65%
Low RiskElevated
Elevated Risk (65%)
The manager highlights meaningful macroeconomic headwinds, specifically identifying renewed US-Iran hostilities in the Strait of Hormuz, crude oil exceeding $100 per barrel, synchronized monetary tightening across the Fed, ECB, and BoJ, and climbing 10-year Treasury yields.
Opportunity Density
65%
ScarceAbundant
Abundant (65%)
Antipodes identifies an expanding set of idiosyncratic opportunities across quality compounders trading at trough multiples, AI infrastructure beneficiaries, and neglected healthcare assets. However, the team explicitly notes finding diminished value in fully priced wafer fabrication equipment and building materials.
Time Horizon
70%
Short-TermLong-Term
Decade+ (70%)
The investment framework operates across a multi-year horizon, explicitly referencing 3-to-5 year holding periods, clinical trial pipelines playing out over coming years, and long-term earnings growth extending through the middle of the next decade.